文献速递贫血与红细胞疾病

达雷妥尤单抗单药治疗难治性温抗体型自身免疫性溶血性贫血与冷凝集素病

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
PubMed 文献 · Blood Adv · 2024-01-01

这项国际回顾性研究纳入19例经重度预处理的难治性自身免疫性溶血性贫血成人患者,评估达雷妥尤单抗单药治疗的疗效与安全性。温抗体型(12例)总缓解率为50%,中位缓解持续时间5.5个月;冷凝集素病(7例)血红蛋白总缓解率为57%。作者认为达雷妥尤单抗可能成为难治性自身免疫性溶血性贫血的治疗选择,其免疫调节作用值得进一步探索。

要点

  • 温抗体型12例总缓解率50%,中位缓解持续时间5.5个月(范围2-12)。
  • 冷凝集素病7例血红蛋白总缓解率57%,7例中3例缓解持续。
  • 达雷妥尤单抗治疗后可见CD38+ T细胞完全清除及T细胞亚群分化改变。

核心结论

  • 数据表明达雷妥尤单抗治疗可能成为难治性自身免疫性溶血性贫血的一种治疗选择。
  • 观察到的免疫调节作用可能有助于临床缓解,值得进一步探索。

研究设计与样本

  • 国际回顾性研究,纳入19例经重度预处理的难治性自身免疫性溶血性贫血成人患者,评估达雷妥尤单抗单药治疗的疗效与安全性。
  • 温抗体型自身免疫性溶血性贫血12例,冷凝集素病7例。
  • 其中2例温抗体型患者前瞻性采集血样进行免疫学分析。

主要发现

  • 温抗体型(n=12)总缓解率为50%,中位缓解持续时间5.5个月(范围2-12),其中2例在6个月和12个月时仍持续缓解。
  • 温抗体型6例无缓解者中4例为Evans综合征。
  • 冷凝集素病(n=7)血红蛋白总缓解率为57%,7例中3例持续缓解。
  • 另1例非贫血冷凝集素病患者因严重肢端发绀接受治疗,达到临床肢端发绀缓解且血红蛋白升高。
  • 6例伴肢端发绀的冷凝集素病患者中4例经达雷妥尤单抗治疗后症状改善。

关键数值与推荐

  • 2例温抗体型患者前瞻性血样显示达雷妥尤单抗治疗后CD38+ T细胞完全清除,T细胞亚群分化改变,细胞活化与增殖能力严重下降。
  • 1例患者CD38+ T细胞再现与疾病复发同时发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 is also expressed by activated T cells, daratumumab may also act via immunomodulatory effects. We evaluated the efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA. In warm AIHA (wAIHA, n = 12), overall response was 50% with a median response duration of 5.5 months (range, 2-12), including ongoing response in 2 patients after 6 and 12 months. Of 6 nonresponders, 4 had Evans syndrome. In cold AIHA (cAIHA, n = 7) overall hemoglobin (Hb) response was 57%, with ongoing response in 3 of 7 patients. One additional patient with nonanemic cAIHA was treated for severe acrocyanosis and reached a clinical acrocyanosis response as well as a Hb increase. Of 6 patients with cAIHA with acrocyanosis, 4 had improved symptoms after daratumumab treatment. In 2 patients with wAIHA treated with daratumumab, in whom we prospectively collected blood samples, we found complete CD38+ T-cell depletion after daratumumab, as well as altered T-cell subset differentiation and a severely diminished capacity for cell activation and proliferation. Reappearance of CD38+ T cells coincided with disease relapse in 1 patient. In conclusion, our data show that daratumumab therapy may be a treatment option for refractory AIHA. The observed immunomodulatory effects that may contribute to the clinical response deserve further exploration.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024. PMID: 38507742. doi:10.1182/bloodadvances.2024012585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。